Hendley & Co. Inc. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% during the first quarter, Holdings Channel reports. The fund owned 26,881 shares of the biopharmaceutical company’s stock after selling 35 shares during the period. Hendley & Co. Inc.’s holdings in Gilead Sciences were worth $1,826,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Bridges Investment Management Inc. raised its stake in shares of Gilead Sciences by 65.6% in the first quarter. Bridges Investment Management Inc. now owns 59,150 shares of the biopharmaceutical company’s stock worth $4,018,000 after buying an additional 23,439 shares during the last quarter. F&V Capital Management LLC raised its stake in shares of Gilead Sciences by 3.1% in the first quarter. F&V Capital Management LLC now owns 79,450 shares of the biopharmaceutical company’s stock worth $5,396,000 after buying an additional 2,425 shares during the last quarter. Triangle Securities Wealth Management raised its stake in shares of Gilead Sciences by 30.5% in the first quarter. Triangle Securities Wealth Management now owns 3,832 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 895 shares during the last quarter. Private Asset Management Inc. raised its stake in shares of Gilead Sciences by 4.1% in the first quarter. Private Asset Management Inc. now owns 115,410 shares of the biopharmaceutical company’s stock worth $7,839,000 after buying an additional 4,582 shares during the last quarter. Finally, Park National Corp OH raised its stake in shares of Gilead Sciences by 24.6% in the first quarter. Park National Corp OH now owns 7,851 shares of the biopharmaceutical company’s stock worth $534,000 after buying an additional 1,550 shares during the last quarter. Institutional investors and hedge funds own 74.02% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.71% during mid-day trading on Wednesday, hitting $73.64. The company had a trading volume of 1,772,962 shares. The firm has a 50-day moving average price of $72.48 and a 200 day moving average price of $68.76. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $82.10. The firm has a market capitalization of $96.17 billion, a P/E ratio of 8.00 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.08 earnings per share. On average, equities research analysts forecast that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (GILD) Shares Sold by Hendley & Co. Inc.” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-sold-by-hendley-co-inc/1495096.html.

A number of equities research analysts have recently weighed in on the company. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 2nd. BMO Capital Markets restated an “outperform” rating and set a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Deutsche Bank AG restated a “buy” rating and set a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Jefferies Group LLC restated a “hold” rating and set a $83.00 price target on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Cowen and Company restated an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research note on Thursday, July 27th. Twelve research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $80.31.

In other Gilead Sciences news, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the transaction, the executive vice president now owns 137,488 shares of the company’s stock, valued at $10,174,112. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Insiders have sold 206,666 shares of company stock valued at $15,223,184 in the last three months. 1.30% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.